Callisto to investigate Atiprimod in carcinoid tumors
Based on the clinical data, the company plans to initiate a new phase I/II trial of Atiprimod in carcinoid cancer patients with advanced tumors that it plans to
The US Food and Drug Administration (FDA) is set to review Kowa Pharmaceuticals America’s new drug application (NDA) for K-911, an investigational once-daily eye drop aimed at reducing intraocular pressure (IOP) in open-angle glaucoma (OAG) or ocular hypertension (OHT) patients.